Help accelerate the diagnosis of hATTR amyloidosis
Process for ensuring a timely diagnosis
Due to the rapid natural progression of the disease, patients with hATTR amyloidosis require an early and accurate diagnosis.1-3
Raise clinical suspicion
Identify the signs through diagnostic toolsa
Select an assessment below to learn more about the diagnostic tools and results
It is also important to remember that the symptoms of hATTR amyloidosis may overlap with those of other diseases. A detailed diagnostic history may help to identify patients with hATTR amyloidosis.
Common misdiagnoses in patients with hATTR amyloidosis2,5,6,9-20
AA=amyloid A; AL=amyloid light chain; ALS=amyotrophic lateral sclerosis; CIDP=chronic inflammatory demyelinating polyneuropathy; wtATTR=wild-type ATTR.
See 2 examples of patients with hATTR amyloidosis you might encounter in your practice. Download now
Options to help confirm a diagnosis5,7,9,a
aNot a comprehensive list of diagnostic tools.
Genetic testing through Alnylam Act®
Genetic testing and counseling may help to:
- Identify risk of disease for patients and their family members
- Shorten the time to diagnosis and prevent misdiagnoses
- Determine if patients are eligible to participate in clinical trials
- Provide information about support resources such as patient advocacy organizations
aThe Alnylam Act® program was developed to reduce barriers to genetic testing and counseling to help people make more informed decisions about their health. While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for healthcare professionals who use this program. Genetic testing is available in the U.S. and Canada. Genetic counseling is only available in the U.S. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.
- Gertz MA. Am J Manag Care. 2017;23(suppl 7):S107-S112.
- Conceição I, González-Duarte A, Obici L, et al. J Peripher Nerv Syst. 2016;21(1):5-9.
- Obici L, Kuks JB, Buades J, et al. Curr Opin Neurol. 2016;29(suppl 1):S27-S35.
- Shin SC, Robinson-Papp J. Mt Sinai J Med. 2012;79(6):733-748.
- Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.
- Castro J, Miranda B, Castro I, et al. Clin Neurophysiol. 2016;127(5):2222-2227.
- Dharmarajan K, Maurer MS. J Am Geriatr Soc. 2012;60(4):765-774.
- Falk RH, Quarta CC. Heart Fail Rev. 2015;20(2):125-131.
- Adams D, Suhr OB, Hund E, et al. Curr Opin Neurol. 2016;29(suppl 1):S14-S26.
- Goyal NA, Mozaffar T. Neurol Genet. 2015;1:e18.
- Zeng L, Alongkronrusmee D, van Rijn RM. J Pain Res. 2017;10:219-228.
- Cortese A, Vegezzi E, Lozza A, et al. J Neurol Neurosurg Psychiatry. 2017;88(5):457-458.
- Adams D, Lozeron P, Lacroix C. Curr Opin Neurol. 2012;25(5):564-572.
- Szigeti K, Lupski JR. Eur J Hum Genet. 2009;17(6):703-710.
- Hovaguimian A, Gibbons CH. Curr Pain Headache Rep. 2011;15(3):193-200.
- Rapezzi C, Longhi S, Milandri A, et al. Amyloid. 2012;19(suppl 1):16-21.
- Linhart A. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Oxford: Oxford PharmaGenesis; 2006. Chapter 20.
- Lalande S, Johnson BD. Drugs Today (Barc). 2008;44(7):503-513.
- Ruberg FL, Berk JL. Circulation. 2012;126(10):1286-1300.
- Kapoor M, Rossor AM, Jaunmuktane Z, et al. Pract Neurol. 2018. 0:1-9. doi:10.1136/practneurol-2018-002098.